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ABSTRACT
Background and Objectives: The aims of this study were to establish a reliable model of chronic mitral regurgitation (MR) 
in rats and verify the pathophysiological features of this model by evaluating cardiac function using serial echocardiography 
and a pressure-volume analysis. Materials and Methods : MR was created in 37 Sprague-Dawley rats by making a hole with 
a 23 gauge needle on the mitral leaflet through the left ventricular (LV) apex under the guidance of transesophageal echo-
cardiography. Results: Serial echocardiograms revealed that the LV began to dilate immediately after the MR operation and 
showed progressive dilation until the 14th week (LV end-systolic dimension at 14 weeks, 4.71±0.25 mm vs. 6.81±0.50 mm 
for sham vs. MR, p<0.01; LV end-diastolic dimension, 8.32±0.42 mm vs. 11.01±0.47 mm, p<0.01). The LV ejection fraction 
tended to increase immediately after the MR operation but started to decrease thereafter and showed a significant difference 
with the sham group from the 14th week (70.0±2.2% vs. 62.1±3.1% for sham vs. MR). In a pressure-volume analysis per-
formed at the 14th week, the LV end-systolic pressure-volume relationship and +dp/dt decreased significantly in the MR 
group. A serial treadmill test revealed that exercise capacity remained in the normal range until the 14th week when it began 
to decrease (exercise duration, 406±45 seconds vs. 330±27 seconds, p<0.01). A pathological analysis showed no significance 
difference in interstitial fibrosis between the two groups. Conclusion: We established a small animal model of chronic MR 
and verified its pathophysiological features. This model may provide a useful tool for future research on MR and volume 
overload heart failure. (Korean Circ J 2011;41:603-611)
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Introduction
Heart failure is a leading cause of death and continues to pro-
vide significant socioeconomic burdens worldwide.
1) Heart 
failure is a clinical syndrome attributed to various causes. Al-
though most patients share the final stage of left ventricular 
(LV) dysfunction, the pathophysiology from initial myocardi-
al damage to LV dysfunction differs in every patient.
2) There-
fore, the study of heart failure requires various animal models 
that mimic the pathogenetic features of heart failure in hu-
mans. In this respect, rat models of LV hypertrophy that lead 
to heart failure have been useful for examining pathogenesis 
and for testing novel heart failure therapeutic options.
3)4) 
Many investigators have scaled down from large animal mo-
dels to rat models because they are easier to manipulate, ch-
eaper to maintain, and similar to the human cardiovascular 
system. Moreover, recent advances in echocardiography and 
micromanometer conductance catheters have made it possi-
ble to reliably evaluate cardiac function in rats.
5)
Mitral regurgitation (MR) is the most common type of val-
vular heart disease that induces LV volume overload. The pre-
valence of MR has been increasing as the mean age of the po-
pulation advances.
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has not been fully understood partly because adequate ani-
mal models are not yet available. Although large animal mo-
dels (dog or sheep)
8)9) have been used, they are limited be-
cause of the small sample sizes of the experimental groups. In 
the present study, we established a reliable small animal mo-
del of chronic MR using rats and verified the pathophysio-
logical features of this model by evaluating cardiac function 
using serial echocardiography and pressure-volume (PV) an-
alysis to provide a useful tool for future research on cardiac 
remodeling in MR and volume-overload heart failure. 
Materials and Methods
In total, 61 Sprague-Dawley (SD) rats (initial weight, 350-
400 g) were used at the age of 10 weeks. The rats were given ac-
cess to tap water and standard rat chow ad libitum and were 
housed in the Laboratory Animal Facility of the Clinical Re-
search Institute of Seoul National University Hospital with a 
12 hours :12 hours light cycle and a temperature of 21°C. The 
experimental protocols were approved by the Institutional 
Animal Care and Use Committee of Seoul National Univer-
sity Hospital. 
 
Creation of mitral regurgitation
Mitral regurgitation was created in 37 of 61 rats 1 week after 
baseline echocardiography, the exercise test, and blood pres-
sure (BP) measurements, as previously described.
11) The rats 
were anesthetized with 3% isoflurane at a rate of 4 L/min oxy-
gen and were intubated with a blunt 16-gauge needle, follow-
ed by mechanical ventilation with an M-683 system (Har-
vard Apparatus Inc., Holliston, MA, USA) under 2-3% isoflu-
rane in a mixture of 50% O2. Body temperature was main-
tained at 37°C by placing the rats on a heating pad during the 
procedure. After successful anesthesia, an intracardiac echo-
cardiographic catheter (AcuNav
TM, Acuson/Siemens Corp, Mo-
untain View, CA, USA) was inserted into the esophagus for 
transesophageal echocardiography. A lateral thoracotomy 
was performed, and the pericardium was opened. The LV was 
gently pressed with a clean cotton swab to accurately locate 
the insertion site of the puncture needle. A needle (23 gauge, 
0.5 mm external diameter) was inserted into the LV via apical 
puncture and was advanced toward the mitral valve to create 
a hole in the leaflet and induce MR under the guidance of tr-
ansesophageal echocardiography (Fig. 1). MR was consider-
ed significant if a regurgitant jet area occupied >45% of the 
left atrium (LA).
10) The sham group (n=24) underwent the same 
A  
C  
B  
D  
Fig. 1. Surgical procedures for creating mitral regurgitation (MR). A: a lateral thoracotomy was performed on the left side of the sternum 
through the 3rd or 4th intercostal space, and a needle was inserted. B: advancing the needle toward the mitral valve leaflet; red arrow indicates 
the needle. C: severe MR events were detected by color Doppler after the MR procedure. D: the MR jet and left atrial area were measured 
1 week after MR development by transthoracic echocardiography.Kyung-Hee Kim, et al.   605
procedure but without damage to the mitral valve. All rats 
were given a 2 mL subcutaneous injection of isotonic saline 
and meloxicam (Boehringer Ingelheim, Germany 0.4 mg/g 
s.c.) postoperatively and cefazolin (50 µg/g i.m.) 2 times per 
day for 2 days to prevent infection.
Echocardiography
Transthoracic echocardiography was performed 1 week 
before and 1, 3, 6, 9, 12, and 14 weeks after the creation of MR 
on spontaneously breathing rats placed in a dorsal recumbent 
position. Rats were lightly sedated with the lowest possible 
dose of isoflurane (initially 4%, then approximately 2-3%) 
mixed with oxygen. Images were acquired with a 9 MHz tr-
ansducer connected to a Toshiba echocardiography machine 
(Nemio, Toshiba Co., Tokyo, Japan). LV septal and posterior 
wall thickness (SWT and PWT, respectively) and the LV end 
diastolic/systolic dimension (EDD/ESD, respectively) were 
measured using M-mode echocardiography at the papillary 
muscle level. The LV ejection fraction (EF) was calculated as 
(LVEDD
2-LVESD
2)/LVEDD
2. LV mass was estimated by a for-
mula previously validated in small animals
11)12) and adjusted 
for body weight: [LV-mass={(SWT+PWT+LVEDD)
3-(LV-
EDD)
3}×1.04]. Color Doppler mapping of MR jets was used 
to semiquantitatively assess the severity of MR.
13) MR jet and 
LA areas were measured in the apical long-axis view, and the 
ratio of MR jet area to the LA areas was calculated (Fig. 1D). 
Early diastolic transmitral flow (E velocity) was measured in 
an apical four-chamber view with a 1.5-mm sized sample vol-
ume placed at the tips of the mitral leaflets. Early diastolic sep-
tal mitral annulus velocity (E’) was assessed by tissue Dop-
pler imaging with a sample volume of 1 mm. All parameters 
were evaluated on an average of five consecutive beats. A sin-
gle echocardiographer, with >500 rat echocardiography cases 
of experience, performed all data acquisition. 
Exercise test and blood pressure monitoring
Maximal exercise capacity was evaluated with the Rota Rod 
Treadmill (Ugo Basile, Comerio, Italy). The rats ran on a kn-
urled drum as the drum rotated to avoid falling off. Animals 
were trained two times before the test to adjust the treadmill. 
Treadmill speed was gradually increased from 3 revolutions 
per minute (rpm) to 15 rpm every 1 minute, and maximum ex-
ercise time was recorded. An observer blinded to the study 
group recorded the immobility response due to exhaustion.
Systolic and diastolic BPs were measured in conscious rats 
using the tail-cuff method (Biopac System Inc., Goleta, CA, 
USA) at 10, 14, 18, and 22 weeks of age. At minimum of 1 day 
was given for the BP measurements after the echocardiograph-
ic examination or exercise test to minimize stress on the animals.
Hemodynamic measurements
At 14 weeks after MR creation, the rats were anesthetized 
with isoflurane and placed in the supine position on a heating 
pad with a rectal probe connected to a thermoregulator. The 
right internal jugular vein was cannulated to administer fluids. 
After an anterior thoracotomy, a microtip PV catheter (SPR-
838, Millar Instruments, Houston, TX, USA) was introduc-
ed into the LV cavity via an apical approach along the longi-
tudinal axis of the heart until stable PV loops were obtain-
ed.
5)14) PV loops were acquired with the ventilator off for 5-10 
seconds after 10 minutes of stabilization. The sampling rate 
was 1,000/s using the ARIA PV conductance system (Millar 
Instruments) coupled to a PowerLab/4SP A/D converter (AD 
Instruments; Mountain View, CA, USA) and a personal com-
puter. To obtain Vo, additional loops were acquired during 
injection of 500 µL of 15% hypertonic saline. Ten to twenty 
successive cardiac cycles were obtained. True corrected vol-
umes were calculated based on the EF on echocardiography 
and saline calibrations, as described previously.
5)15) Analyses 
of the loops were performed using a commercially available 
cardiac PV analysis program, PVAN 3.5 (Millar Instruments). 
Heart rate, maximal LV systolic pressure, LV end-diastolic 
pressure (EDP), mean arterial pressure, maximal slope of sys-
tolic pressure increment (+dP/dt), the decrease in diastolic 
pressure (-dP/dt), the time constant of LV pressure decay (τ), 
stroke volume (SV), and end-systolic/diastolic volume (ESV/ 
EDV) were calculated. Additionally, the end-systolic pressure 
volume relationship (ESPVR), the SW-EDV relationship {pre-
load recruitable stroke work (PRSW)}, the dP/dtmax-EDV re-
lationship, and the end-diastolic PV relationship (EDPVR) 
were measured by transient occlusion of the inferior vena 
cava with a silk snare suture.
16) 
Survival assessment 
The survival analysis was performed for animals that sur-
vived the acute stage of MR (2 weeks after the surgical proce-
dure) until 14 weeks after MR when a hemodynamic study 
was performed. Ten rats from each group were randomly cho-
sen and followed up for 10 months to evaluate long-term survival.
Histological analysis
After the hemodynamic measurements, the rats were eu-
thanized and the hearts and lungs were harvested. Hearts and 
lungs were dissected after they were rinsed with isotonic sa-
line and weighed. The weights of the hearts and lungs were 
normalized to body weight and used as an index of ventricu-
lar hypertrophy and pulmonary congestion, respectively. The 
LV was then fixed with 4% paraformaldehyde and embedd-
ed in paraffin. The tissue was sectioned into 4 µm sections, 
stained with Masson’s trichrome to evaluate the degree of fi-
brosis and with picrosirius red to measure collagen deposi-
tion. The measurement of the area of fibrosis was quantified 
as the ratio of the area of fibrosis surrounding the total myo-
cardium area using NIH image analysis software (Image J ver. 606   Hemodynamic Study of Mitral Regurgitation in a Rat Model
1.38, National Institutes of Health).
17) An arterial blood sam-
ple was collected from the abdominal aorta immediately af-
ter the hemodynamic measurements. After centrifugation 
(3,000×g), the plasma was stored at -80°C and assayed for 
plasma brain natriuretic peptide (BNP). BNP concentration 
was assessed with a rat ELISA rat BNP-45 kit (Assaypro, St. 
Charles, MO, USA).
 
Statistical analysis 
The results are expressed as means±SD. The unpaired two-
sided Student’s t-test was used to compare continuous vari-
ables between groups, as appropriate. The time course of pa-
rameter changes was compared between the sham and MR 
groups using a repeated-measures analysis of variance. Sur-
vival rate was evaluated by the Kaplan-Meier method. All st-
atistical analyses were performed using SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA), and p<0.05 were considered 
statistically significant. 
Results
Two rats died of bleeding and one rat died of an unknown 
cause after surgery, making the operative mortality 8% (3/37). 
Four rats died during the acute stage within 2 weeks after 
the MR operation (12%, 4/34) due to pulmonary edema (3/4) 
and an unknown cause (1/4). No death was noted in the sham 
group. Two weeks after surgery, 54 rats (24 in the sham gr-
oup and 30 in the MR group) remained alive for the study. 
The mean weight gain of the MR rats during the 14 week pe-
riod tended to lag behind the sham rats, but no statistical differ-
ence was observed (Fig. 2A)
 
Mitral regurgitation severity and Doppler 
echocardiographic data (Table 1)
Mitral regurgitation was created successfully in all rats. Mean 
MR jet area was 15±3 mm
2, and the mean ratio of MR jet area 
to LA area was 56±8% at 1 week. No MR occurred in the 
Fig. 2. Left ventricular remodeling after mitral regurgitation. A: body weight changes between the mitral regurgitation (MR) and the sham group. 
B: serial changes in cardiac remodeling using echocardiographic measurements. Time course of typical M-mode echocardiograms. End-sys-
tolic dimension (mm), end-diastolic dimension (mm), left ventricular (LV) ejection fraction (%), LV mass index. g/kg. *p<0.05. C: serial changes 
in blood pressure and heart rate. MR: mitral regurgitation, LV: left ventricular, LVPWT: left ventricular posterior wall thickness, HR: heart rate, 
SBP: systolic blood pressure, DBP: diastolic blood pressure.
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sham group. Mitral E velocity increased at 1 week (65.2±7.1 
cm/s vs. 105.1±15.1 cm/s, p<0.01) in the MR group, whereas 
it did not change in the sham group (66.4±6.4 cm/s vs. 64.5± 
5.5 cm/s, p=0.76). However, E velocity was similar at 6 weeks 
after MR and throughout the study period. So, the E/E’ ratio 
was not different between the groups at 6 weeks after the op-
eration (Supplementary Fig. 1). 
Left ventricular remodeling after mitral regurgitation
Fig. 2B demonstrates the time-dependent changes in LV 
diameter and the EF and LV mass index. Baseline examina-
tions showed no differences in LV diameters between the two 
groups (LVESD, 4.02±0.27 mm vs. 4.03±0.24 mm, LVEDD; 
7.31±0.34 mm vs. 7.34±0.29 mm for the sham and MR gr-
oups, respectively p=0.82). The LV started to dilate immedia-
tely after MR and showed progressive dilation until the 14th 
week. Significant differences in LVEDD were observed be-
tween the groups from the 3rd week after MR, whereas LV-
ESD did not increase significantly until the 6th week. LVEF 
tended to increase immediately after MR, suggesting hyper-
dynamic systolic function but started to decrease thereafter. 
A significant difference was observed in LVEF between the 
groups at the 14th week. LV mass index progressively in-
creased in the MR group. No significant changes were ob-
served for BP or heart rate between the groups (Fig. 2C)
Hemodynamic measurements and plasma brain 
natriuretic peptide level
The 15 MR rats and 14 sham rats underwent an invasive 
hemodynamic assessment randomly and were sacrificed for 
the pathological analysis (Table 2). Heart rate, LVEDP, -dP/
dt, τ (Weiss, Glantz), and the EDPVR slope were not differ-
ent between the groups. However, ESV, EDV, and SV were gr-
Table 1. Echocardiographic characteristics at 14 weeks after mi-
tral regurgitation (25 weeks of age)
Variables
Sham group
(n=24)
MR group
(n=25)
p
HR (beats/min)* 312.8±27.3 318.3±15.7 0.84
EF (%) 70.0±2.2 62.1±3.1 <0.01
EDD (mm) 08.32±0.42 011.1±0.47 <0.01
ESD (mm) 04.57±0.25 06.81±0.50 <0.01
SWT (mm) 01.35±0.07 01.30±0.08  0.10
PWT (mm) 01.32±0.08 01.19±0.06  0.04
E/E’ 12.0±3.2 12.5±5.5  0.75
LV mass index (mg/g)* 01.31±0.23 02.04±0.29 <0.01
Data are means±SD. *Heart rate and LV mass were estimated in vivo 
by echocardiography. HR: heart rate, EF: ejection fraction, SWT: 
end-diastolic wall thickness of the interventricular septum, PWT: 
end diastolic wall thickness of the posterior wall, EDD: end diastolic 
dimension, ESD: end systolic dimension, E/E’: mitral inflow E-
septal tissue Doppler velocity E’ ratio
Supplementary Fig. 1. A: serial change in mitral inflow E-septal tissue Doppler velocity E’ ratio (E/E’). *p<0.05. B: a representative image at 
9 weeks after development of mitral regurgitation.
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Table 2. Hemodynamic parameters 
Variables
Sham group
(n= 14)
MR group
(n=15)
p
HR (beats/min) 315.5±36.30 321.1±24.7 0.27
ESV (µL) 126.2±25.90 390.2±47.4 <0.01
EDV (µL) 403.9±55.60 0998.7±134.7 <0.01
EF (%) 69.0±2.80 60.9±3.8 <0.01
SV (µL) 277.7±31.80 608.5±92.3 <0.01
LV ESP (mm Hg) 90.0±14.3 087.5±13.4 0.57
LV EDP (mm Hg) 10.1±3.10 12.0±5.0 0.09
+dP/dt (mm Hg/s) 5951.1±1002.5 4260.8±603.3 0.04
-dP/dt (mm Hg/s) -3954.7±981.700 -3535.5±585.50 0.31
τ (Weiss) (ms) 20.3±14.5 19.8±4.2 0.84
τ (Glantz) (ms) 14.7±1.20 15.5±4.3 0.61
ESPVR (mm Hg/µL) 0.371±0.153 00.130±0.396 0.02
EDPVR (mm Hg/µL) 0.016±0.006 00.012±0.005 0.32
PRSW (mm Hg) 111.1±24.50 068.7±14.2 0.01
dP/dtmax-EDV  
  (mm Hg/s · µL)
21.26±4.500 8.03±3.4 0.01
Mean±standard deviation. MR: mitral regurgitation group, HR: 
heart rate, ESV: end-systolic volume, EDV: end-diastolic volume, SV: 
stroke volume, LV ESP: LV end systolic pressure, LV EDP: LV end 
diastolic pressure, ESPVR: end systolic pressure-volume relation-
ship, EDPVR: end diastolic pressure-volume relationship608   Hemodynamic Study of Mitral Regurgitation in a Rat Model
eater in the MR group than those in the sham group. The ES-
PVR slope, +dp/dt, and EF decreased significantly in the MR 
group, indicating contractile dysfunction (Fig. 3). 
The plasma BNP concentration of the sham rats at the 14th 
week after MR was below the detection limit (<30 pg/mL). 
Plasma BNP concentration increased to 105±62 pg/mL in 
rats with MR.
Exercise capacity 
No difference in exercise duration was observed between 
the groups until the 14th week after MR when exercise du-
ration became shorter in the MR group (406±45 seconds vs. 
330±27 seconds, p<0.01) (Fig. 4). Thereafter, exercise capaci-
ty was impaired progressively (at 24 weeks, 370±40 seconds 
vs. 180±14 seconds, p<0.01).
Survival analysis and pathological results 
Fig. 5 shows the Kaplan-Meier survival curves in the MR 
and sham groups. The survival rate at the 14th week after MR 
was worse in the MR group (83.3%, 25/30) than that in the 
sham group (100%; 24/24, p=0.038). Among 30 rats with ch-
ronic MR and 24 sham rats, 10 rats in each group were ran-
domly followed up for 10 months. The 10-month survival rate 
was significantly lower in the MR group than that in the sham 
group (50% for MR vs. 90% for sham; p<0.01).
A gross pathological examination showed that the heart 
was significantly enlarged in the MR group with eccentric hy-
pertrophy at 14 weeks postoperatively (Table 3) (Fig. 6). How-
ever, quantitative measurements of interstitial fibrosis and 
collagen showed no differences between the groups. 
Discussion
A wide variety of small animal heart failure models are av-
ailable.
3)18) The role of these models for understanding the 
disease and developing new treatment cannot be overemph-
asized. In the present study, we established a small animal 
MR model in rats and evaluated survival, exercise capacity, 
and LV remodeling using serial echocardiographic follow-up 
and a PV analysis. We believe that this model will provide a 
Fig. 4. A comparison of exercise capacity measured by running 
duration to exhaustion in the two groups during the compensated 
and decompensated phases. p<0.01.
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Table 3. Pathology results 
Variables
Sham group
(n= 14)
MR group
(n= 15)
p
BW (g) 598.0±52.0 561.0±48.8 0.34
Heart (g) 01.16±0.11 01.52±0.45 0.02
Lung (g) 01.66±0.15 01.81±0.20 0.04
Liver (g) 19.7±2.5 018.2±1.95 0.66
Heart/BW (mg/g) 01.94±0.34 02.71±0.62 <0.01
Lung/BW (mg/g) 02.81±0.29 03.23±0.31 0.01
Liver/BW (mg/g) 33.1±2.9 32.5±3.5 0.76
Interstitial fibrosis (%) 04.9±2.6 05.0±3.1  0.88
Interstitial collagen (%) 03.7±1.7 03.7±2.1 0.90
Values are means±SDs. BW: body weight
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Fig. 3. The mitral regurgitation (MR) model phenotype. Pressure-
volume loops depict the features of MR. The slope of the end-sys-
tolic pressure volume relation (ESPVR, red slope) is an excellent 
load-independent index of myocardial contractility. Compared with 
the sham heart (left) the MR heart is enlarged, and has depressed 
contractility.Kyung-Hee Kim, et al.   609
reference for future research and enhance our understanding 
of the pathophysiology and the development of new therapeu-
tics for MR. Compared to large animal models,
8)19)20) which 
have been used for MR experiments, this model has several 
advantages. First, LV remodeling and hemodynamic changes 
can be followed up in a shorter period of time, and survival 
analysis can be performed. Additionally, the costs are much 
lower; thus, the experiment is more feasible. 
In their pioneering work, Pu et al.
10)21) developed an MR rat 
model for the first time. However, their report lacked details 
about the animal model, LV remodeling, exercise capacity, 
and histological findings that are critically important for fu-
ture research. In the present study, we established a reliable 
small animal model of chronic MR using rats and verified the 
pathophysiological features of this model using serial echo-
cardiography, PV analyses, an exercise test, and immunohisto-
chemistry. We focused on several aspects to make the model 
useful for future experiments. Our first concern was that he-
art size and gender have been neglected in some previous ex-
periments. In our pilot study, we found that rats showed ra-
pid growth of the heart between 8 and 10 weeks of age (LV-
ESD, 3.40±0.15 mm vs. 4.02±0.27 mm; LVEDD, 6.41±0.34 
mm vs. 7.31±0.34 mm for 8 vs. 10 weeks of age, p<0.01); thus, 
this period was not optimal for evaluating LV remodeling. 
Therefore, in this study, we used only 10 week old male rats. 
Second, we determined an adequate severity of MR to induce 
substantial LV remodeling without excessive mortality dur-
ing the acute phase. We found that a 23G needle with an ex-
ternal diameter of 0.5 mm was the best for this purpose. At 
the postmortem study, the mean area of the hole was 0.79± 
0.34 mm
2. Obviously, a “learning curve” was noted in our 
experience. In our first pilot study, the MR operation was suc-
cessful in only three of nine (33%) rats. It took 4 months for 
a consistent MR formation technique to develop. Interest-
ingly, the mitral leaflet hole spontaneously regressed in some 
of the animals in our pilot study. Thus, confirmation of MR 
by serial echocardiography and direct visualization of the 
hole at harvest time were important.
In our chronic MR animal model, we described the natural 
course of LV remodeling in detail, which is important for fu-
ture research. The acute stage was defined from creation of 
MR to the 2nd week after MR. We observed slight increases 
in the LV diastolic dimension without change in the systolic 
dimension; thus, hyperdynamic LV systolic function. Dur-
ing this stage, LV wall thinning occurred as the LV began to 
dilate. Four rats died during the acute stage (12%, 4/34) due 
to pulmonary edema (lung weight/body weight, mg/g; 1.94± 
0.34 in the sham group vs. 9.51±0.57 mg/g for the acute MR 
group). A chronic compensated stage was defined from the 
3rd week to around the 14th week. In this stage, LV diastolic 
and systolic volume increased constantly. Although LVEF re-
mained in the normal range, it decreased significantly in the 
MR group from the 12th week. At the 14th week, load-inde-
pendent contractile indices such as ESPVR, dP/dtmax-EDV, 
and PRSW were significantly lower in the MR group, where-
as diastolic parameters such as EDPVR, -dP/dt, and tau were 
not different between the groups. Indeed, MR is one of the 
very few cardiac diseases in which diastolic function is su-
pernormal.
22)23) Corin et al.
23) showed that the chronic adap-
tation to volume overload in chronic MR tends to decrease 
LV chamber stiffness. They demonstrated that elevated ab-
solute and normalized diastolic filling rates and increased ab-
solute dimension lengthening are found in chronic MR irre-
spective of systolic function. Additionally, we did not find 
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Fig. 6. Comparison of pathological results. Eccentric hypertrophy developed (E) and left ventricular mass increased (F). Masson’s trichrome 
staining showed no significant difference in interstitial fibrosis (B, F, C and G). Picrosirius red staining showed similar collagen content in 
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any changes in the LV collagen fraction or fibrosis in this stage 
of MR. However, the differing results regarding the effects of 
volume overload on collagen turnover may be due to species 
differences, the severity of volume overload, and the exami-
nation stage 
24-26) and need to be further investigated. Decom-
pensation seemed to begin after the 14th week and became 
evident between the 20th and 26th week when mortality in-
creased dramatically. 
 
Study limitations
The development of miniaturized conductance catheters 
has enabled evaluation in the PV plane and allowed quantific-
ation of LV volumes and load-independent indices of con-
tractility.
27)28) However, because of methodological limitations, 
calibration of the volume signal remains challenging. Two ap-
proaches are generally taken with regards to the actual calibr-
ation procedure. One is cuvette calibration, while the other 
is an aortic flow calibration. However, in our experience, the 
cuvette method may yield inaccurate values, as the cylinders 
do not reflect the current distribution in the rat heart. The 
aortic flow measurement would underestimate LV volumes 
because of the MR. Therefore, in the present study, true vol-
umes were calculated with a correction based on the LV EF 
using echocardiography and a saline calibration for Vo. The 
last echocardiography was performed just before the chest 
was opened at the 14th week after MR. An echocardiographic 
examination was performed with isoflurane anesthesia to 
maintain the same physiological conditions. 
Conclusion
We established a small animal chronic MR model and veri-
fied the pathophysiological features of this model using serial 
echocardiography, a treadmill test, PV analyses, and a survi-
val analysis. This model may provide a useful tool for future 
research in MR and volume overload heart failure.
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